001048920 001__ 1048920
001048920 005__ 20251208091715.0
001048920 0247_ $$2CORDIS$$aG:(EU-Grant) 101124542$$d101124542
001048920 0247_ $$2CORDIS$$aG:(EU-Call)ERC-2023-COG$$dERC-2023-COG
001048920 0247_ $$2originalID$$acorda__h2020::101124542
001048920 035__ $$aG:(EU-Grant)101124542
001048920 150__ $$a
Deciphering fibrosis reversal mechanisms in chronic blood cancer for identification of novel predictive and therapeutic strategies
$$y2024-04-01 - 2029-03-31
001048920 372__ $$aERC-2023-COG$$s2024-04-01$$t2029-03-31
001048920 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
001048920 680__ $$a
Is it possible to reverse fibrosis? When there is injury or damage to an organ, the normal healing process involves the formation of new tissue. When this process becomes dysregulated, it leads to the formation of excessive fibrous connective tissue causing fibrosis. Funded by the European Research Council, the Rewind-MF project focuses on primary myelofibrosis, a blood malignancy associated with the activation of fibrosis-driving cells in the bone marrow. The study explores the reversibility of fibrosis, particularly in cases where allogeneic stem cell transplantation is not a viable option. By delving into the mechanisms of reversing fibrosis, researchers expect to identify therapeutic targets and understand how blood cancer is sustained in the bone marrow.

001048920 909CO $$ooai:publications.rwth-aachen.de:1022762$$pauthority:GRANT$$pauthority
001048920 980__ $$aG
001048920 980__ $$aCORDIS
001048920 980__ $$aAUTHORITY